Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Stock Competitors & Peer Comparison

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, VRTX has a market cap of 128.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while VRTX trades at $505.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas VRTX's P/E ratio is 26.58. In terms of profitability, NBIX's ROE is +0.21%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, NBIX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check VRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, REGN has a market cap of 82.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while REGN trades at $803.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas REGN's P/E ratio is 17.61. In terms of profitability, NBIX's ROE is +0.21%, compared to REGN's ROE of +0.14%. Regarding short-term risk, NBIX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check REGN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NBIX's ROE is +0.21%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, NBIX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check VRNA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ARGX has a market cap of 52.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ARGX trades at $851.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ARGX's P/E ratio is 76.83. In terms of profitability, NBIX's ROE is +0.21%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, NBIX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ARGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RVMDW has a market cap of 44B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RVMDW trades at $11.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RVMDW's P/E ratio is -1.55. In terms of profitability, NBIX's ROE is +0.21%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, NBIX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RVMDW's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RVMD trades at $203.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RVMD's P/E ratio is -23.10. In terms of profitability, NBIX's ROE is +0.21%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, NBIX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RVMD's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NBIX's ROE is +0.21%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NBIX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check SGEN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ONC has a market cap of 37.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ONC trades at $347.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ONC's P/E ratio is 61.18. In terms of profitability, NBIX's ROE is +0.21%, compared to ONC's ROE of +0.14%. Regarding short-term risk, NBIX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ONC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ALNY trades at $228.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ALNY's P/E ratio is 41.20. In terms of profitability, NBIX's ROE is +0.21%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, NBIX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ALNY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, INSM has a market cap of 26.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while INSM trades at $123.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas INSM's P/E ratio is -27.08. In terms of profitability, NBIX's ROE is +0.21%, compared to INSM's ROE of -1.11%. Regarding short-term risk, NBIX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check INSM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ROIV trades at $36.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ROIV's P/E ratio is -34.44. In terms of profitability, NBIX's ROE is +0.21%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, NBIX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ROIV's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MRNA has a market cap of 25.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MRNA trades at $63.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MRNA's P/E ratio is -7.77. In terms of profitability, NBIX's ROE is +0.21%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, NBIX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MRNA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while INCY trades at $120.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas INCY's P/E ratio is 16.15. In terms of profitability, NBIX's ROE is +0.21%, compared to INCY's ROE of +0.30%. Regarding short-term risk, NBIX is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check INCY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BNTX has a market cap of 23.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BNTX trades at $93.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BNTX's P/E ratio is -16.84. In terms of profitability, NBIX's ROE is +0.21%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, NBIX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BNTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, UTHR has a market cap of 21.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while UTHR trades at $499.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas UTHR's P/E ratio is 17.88. In terms of profitability, NBIX's ROE is +0.21%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, NBIX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check UTHR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NBIX's ROE is +0.21%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, NBIX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BGNE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, GMAB has a market cap of 19.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while GMAB trades at $31.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas GMAB's P/E ratio is 24.07. In terms of profitability, NBIX's ROE is +0.21%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, NBIX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check GMAB's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.21%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, NBIX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DNA-WT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BBIO trades at $79.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BBIO's P/E ratio is -21.35. In terms of profitability, NBIX's ROE is +0.21%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, NBIX is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BBIO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ASND has a market cap of 15.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ASND trades at $248.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ASND's P/E ratio is -102.69. In terms of profitability, NBIX's ROE is +0.21%, compared to ASND's ROE of -56.42%. Regarding short-term risk, NBIX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ASND's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while JAZZ trades at $244.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas JAZZ's P/E ratio is 9.13. In terms of profitability, NBIX's ROE is +0.21%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, NBIX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check JAZZ's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BMRN has a market cap of 13B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BMRN trades at $67.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BMRN's P/E ratio is 32.38. In terms of profitability, NBIX's ROE is +0.21%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, NBIX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BMRN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while EXEL trades at $51.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas EXEL's P/E ratio is 14.64. In terms of profitability, NBIX's ROE is +0.21%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, NBIX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check EXEL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NBIX's ROE is +0.21%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NBIX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check KRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ARWR trades at $86.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ARWR's P/E ratio is -38.51. In terms of profitability, NBIX's ROE is +0.21%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, NBIX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ARWR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MDGL trades at $507.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MDGL's P/E ratio is -39.65. In terms of profitability, NBIX's ROE is +0.21%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, NBIX is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MDGL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while HALO trades at $98.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas HALO's P/E ratio is 18.41. In terms of profitability, NBIX's ROE is +0.21%, compared to HALO's ROE of +1.81%. Regarding short-term risk, NBIX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check HALO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TECH trades at $72.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TECH's P/E ratio is 37.32. In terms of profitability, NBIX's ROE is +0.21%, compared to TECH's ROE of +0.09%. Regarding short-term risk, NBIX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check TECH's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NBIX's ROE is +0.21%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NBIX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RNAM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, AXSM has a market cap of 11B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while AXSM trades at $213.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas AXSM's P/E ratio is -55.79. In terms of profitability, NBIX's ROE is +0.21%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, NBIX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check AXSM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while SMMT trades at $13.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas SMMT's P/E ratio is -8.34. In terms of profitability, NBIX's ROE is +0.21%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, NBIX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check SMMT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PRAX trades at $366.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PRAX's P/E ratio is -28.37. In terms of profitability, NBIX's ROE is +0.21%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, NBIX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PRAX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PTGX trades at $155.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PTGX's P/E ratio is 150.58. In terms of profitability, NBIX's ROE is +0.21%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, NBIX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PTGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while KRYS trades at $332.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas KRYS's P/E ratio is 41.64. In terms of profitability, NBIX's ROE is +0.21%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NBIX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check KRYS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while KYMR trades at $117.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas KYMR's P/E ratio is -36.68. In terms of profitability, NBIX's ROE is +0.21%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, NBIX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check KYMR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NBIX's ROE is +0.21%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NBIX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RXDX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, IONS has a market cap of 9.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while IONS trades at $57.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas IONS's P/E ratio is -33.28. In terms of profitability, NBIX's ROE is +0.21%, compared to IONS's ROE of -1.11%. Regarding short-term risk, NBIX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IONS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CYTK has a market cap of 9.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CYTK trades at $74.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CYTK's P/E ratio is -11.83. In terms of profitability, NBIX's ROE is +0.21%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, NBIX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CYTK's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas NUVL's P/E ratio is -21.79. In terms of profitability, NBIX's ROE is +0.21%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, NBIX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check NUVL's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, SYRE has a market cap of 9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while SYRE trades at $103.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas SYRE's P/E ratio is -53.14. In terms of profitability, NBIX's ROE is +0.21%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, NBIX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check SYRE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CRNX trades at $84.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CRNX's P/E ratio is -16.81. In terms of profitability, NBIX's ROE is +0.21%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, NBIX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CRNX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ABVX trades at $118.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ABVX's P/E ratio is -62.36. In terms of profitability, NBIX's ROE is +0.21%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, NBIX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ABVX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NBIX's ROE is +0.21%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NBIX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check IMGN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, IMVT has a market cap of 8.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while IMVT trades at $41.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas IMVT's P/E ratio is -14.83. In terms of profitability, NBIX's ROE is +0.21%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, NBIX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check IMVT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PCVX trades at $58.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PCVX's P/E ratio is -7.61. In terms of profitability, NBIX's ROE is +0.21%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, NBIX is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check PCVX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NBIX's ROE is +0.21%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, NBIX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check BPMC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while APGE trades at $134.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas APGE's P/E ratio is -31.07. In terms of profitability, NBIX's ROE is +0.21%, compared to APGE's ROE of -0.30%. Regarding short-term risk, NBIX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check APGE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ALKS trades at $49.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ALKS's P/E ratio is 51.64. In terms of profitability, NBIX's ROE is +0.21%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, NBIX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ALKS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CERE's P/E ratio is -16.47. In terms of profitability, NBIX's ROE is +0.21%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NBIX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CERE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while IBRX trades at $7.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas IBRX's P/E ratio is -7.80. In terms of profitability, NBIX's ROE is +0.21%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, NBIX is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check IBRX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RYTM trades at $115.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RYTM's P/E ratio is -37.13. In terms of profitability, NBIX's ROE is +0.21%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, NBIX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RYTM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TGTX trades at $48.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TGTX's P/E ratio is 17.66. In terms of profitability, NBIX's ROE is +0.21%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, NBIX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TGTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NBIX's ROE is +0.21%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, NBIX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MTSR's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NBIX's ROE is +0.21%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, NBIX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MRUS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ACLX's P/E ratio is -28.27. In terms of profitability, NBIX's ROE is +0.21%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NBIX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ACLX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ORKA has a market cap of 6.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ORKA trades at $111.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ORKA's P/E ratio is -57.24. In terms of profitability, NBIX's ROE is +0.21%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, NBIX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ORKA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CGON trades at $75.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CGON's P/E ratio is -27.89. In terms of profitability, NBIX's ROE is +0.21%, compared to CGON's ROE of -0.25%. Regarding short-term risk, NBIX is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CGON's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RETA's P/E ratio is -66.29. In terms of profitability, NBIX's ROE is +0.21%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NBIX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RETA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while BLTE trades at $162.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas BLTE's P/E ratio is -87.06. In terms of profitability, NBIX's ROE is +0.21%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, NBIX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check BLTE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while DNTH trades at $115.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas DNTH's P/E ratio is -27.94. In terms of profitability, NBIX's ROE is +0.21%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, NBIX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DNTH's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while COGT trades at $37.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas COGT's P/E ratio is -17.98. In terms of profitability, NBIX's ROE is +0.21%, compared to COGT's ROE of -0.73%. Regarding short-term risk, NBIX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check COGT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ERAS trades at $18.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ERAS's P/E ratio is -19.76. In terms of profitability, NBIX's ROE is +0.21%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, NBIX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ERAS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, SRRK has a market cap of 6.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while SRRK trades at $52.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas SRRK's P/E ratio is -15.22. In terms of profitability, NBIX's ROE is +0.21%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, NBIX is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check SRRK's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CNTA's P/E ratio is -22.63. In terms of profitability, NBIX's ROE is +0.21%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, NBIX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CNTA's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CAI has a market cap of 6.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CAI trades at $21.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CAI's P/E ratio is 61.25. In terms of profitability, NBIX's ROE is +0.21%, compared to CAI's ROE of +0.19%. Regarding short-term risk, NBIX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CAI's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MIRM trades at $100.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MIRM's P/E ratio is -6.92. In terms of profitability, NBIX's ROE is +0.21%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, NBIX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MIRM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, XENE has a market cap of 6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while XENE trades at $62.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas XENE's P/E ratio is -13.27. In terms of profitability, NBIX's ROE is +0.21%, compared to XENE's ROE of -0.44%. Regarding short-term risk, NBIX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check XENE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PTCT has a market cap of 6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PTCT trades at $71.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PTCT's P/E ratio is -30.77. In terms of profitability, NBIX's ROE is +0.21%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, NBIX is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check PTCT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while LGND trades at $294.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas LGND's P/E ratio is 32.34. In terms of profitability, NBIX's ROE is +0.21%, compared to LGND's ROE of +0.20%. Regarding short-term risk, NBIX is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check LGND's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, DFTX has a market cap of 5.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while DFTX trades at $42.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas DFTX's P/E ratio is N/A. In terms of profitability, NBIX's ROE is +0.21%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, NBIX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check DFTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TVTX trades at $62.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TVTX's P/E ratio is -138.09. In terms of profitability, NBIX's ROE is +0.21%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, NBIX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TVTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NBIX's ROE is +0.21%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, NBIX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CDTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NBIX's ROE is +0.21%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NBIX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ABCM's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NBIX's ROE is +0.21%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NBIX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ISEE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas APLS's P/E ratio is 38.35. In terms of profitability, NBIX's ROE is +0.21%, compared to APLS's ROE of +0.40%. Regarding short-term risk, NBIX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check APLS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CRSP trades at $53.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CRSP's P/E ratio is -11.25. In terms of profitability, NBIX's ROE is +0.21%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, NBIX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CRSP's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while DYN trades at $25.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas DYN's P/E ratio is -8.06. In terms of profitability, NBIX's ROE is +0.21%, compared to DYN's ROE of -0.64%. Regarding short-term risk, NBIX is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check DYN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ACAD trades at $28.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ACAD's P/E ratio is 13.71. In terms of profitability, NBIX's ROE is +0.21%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, NBIX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ACAD's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TERN's P/E ratio is -51.41. In terms of profitability, NBIX's ROE is +0.21%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NBIX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check TERN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while EWTX trades at $44.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas EWTX's P/E ratio is -23.88. In terms of profitability, NBIX's ROE is +0.21%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, NBIX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check EWTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MANE trades at $112.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MANE's P/E ratio is -35.90. In terms of profitability, NBIX's ROE is +0.21%, compared to MANE's ROE of -0.29%. Regarding short-term risk, NBIX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check MANE's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas FOLD's P/E ratio is -161.00. In terms of profitability, NBIX's ROE is +0.21%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NBIX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check FOLD's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NBIX's ROE is +0.21%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, NBIX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check AKRO's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CELC trades at $92.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CELC's P/E ratio is -23.59. In terms of profitability, NBIX's ROE is +0.21%, compared to CELC's ROE of -3.51%. Regarding short-term risk, NBIX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check CELC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NBIX's ROE is +0.21%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NBIX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check ALPN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RLAY trades at $19.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RLAY's P/E ratio is -12.65. In terms of profitability, NBIX's ROE is +0.21%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, NBIX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check RLAY's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PBLS trades at $37.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PBLS's P/E ratio is -42.12. In terms of profitability, NBIX's ROE is +0.21%, compared to PBLS's ROE of N/A. Regarding short-term risk, NBIX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check PBLS's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas OPT's P/E ratio is -1.52. In terms of profitability, NBIX's ROE is +0.21%, compared to OPT's ROE of +1.18%. Regarding short-term risk, NBIX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check OPT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas PRTC's P/E ratio is -3.78. In terms of profitability, NBIX's ROE is +0.21%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, NBIX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check PRTC's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ELVN trades at $58.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ELVN's P/E ratio is -35.22. In terms of profitability, NBIX's ROE is +0.21%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, NBIX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ELVN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TNGX has a market cap of 4.2B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TNGX trades at $25.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TNGX's P/E ratio is -30.84. In terms of profitability, NBIX's ROE is +0.21%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, NBIX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check TNGX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NBIX's ROE is +0.21%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NBIX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check MRTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while TLX trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas TLX's P/E ratio is -642.39. In terms of profitability, NBIX's ROE is +0.21%, compared to TLX's ROE of -0.02%. Regarding short-term risk, NBIX is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check TLX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, ADPT has a market cap of 4B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while ADPT trades at $24.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas ADPT's P/E ratio is -60.34. In terms of profitability, NBIX's ROE is +0.21%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, NBIX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for NBIX.Check ADPT's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while DNLI trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas DNLI's P/E ratio is -8.47. In terms of profitability, NBIX's ROE is +0.21%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, NBIX is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check DNLI's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while VKTX trades at $33.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas VKTX's P/E ratio is -8.02. In terms of profitability, NBIX's ROE is +0.21%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, NBIX is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check VKTX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas CPRX's P/E ratio is 12.30. In terms of profitability, NBIX's ROE is +0.21%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NBIX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check CPRX's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while LEGN trades at $20.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas LEGN's P/E ratio is -29.96. In terms of profitability, NBIX's ROE is +0.21%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, NBIX is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check LEGN's competition here

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NBIX stands at 15.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NBIX is priced at $152.72 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NBIX currently has a P/E ratio of 22.07, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NBIX's ROE is +0.21%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NBIX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for NBIX.Check RYZB's competition here